Accelrys nabs QUMAS for $50 million

Acquisition expands Accelrys' management services offerings

Kelsey Kaustinen
SAN DIEGO—Accelrys, Inc. has announced the acquisition of Cork, Ireland-based QUMAS, a global provider of cloud-based and on-premises enterprise compliance software for regulatory and quality operations for the life sciences and other industries. Accelrys will acquire all of QUMAS’ outstanding capital stock, for which the latter’s shareholders will receive approximately $50 million in cash, subject to working capital and other adjustments. The acquisition is expected to be neutral to Accelrys’ non-GAAP earnings per share for 2013, on $1 million to $2 million in non-GAAP revenue contribution.
 
“In connecting science to business and in bridging the scientific and business communities through our compliance and quality solutions, QUMAS is delighted to join forces with Accelrys to help deliver this comprehensive, single-source compliance solution for the lab-to-plant continuum,” Kevin O’Leary, CEO of QUMAS, said in a press release. “Joining the market leader in scientific innovation lifecycle management enables QUMAS to extend its strong customer momentum into other business areas currently served by Accelrys.”
 
QUMAS provides an electronic document management application with related R&D submission and QA documentation packages based on customer and industry requirements and practices. The company’s business process management applications include CAPA, audit, change control, deviation, complaint and other critical process packages will pre-defined and pre-tested software configurations for common compliance issues.
 
“As Accelrys continues to extend its research, laboratory and manufacturing informatics capabilities to deliver first-in-class scientific innovation lifecycle management solutions, we’re delighted to welcome the QUMAS team and the extensive compliance, quality and regulatory expertise they bring to our company,” Max Carnecchia, Accelrys president and CEO, commented in a statement. “Integrating QUMAS solutions into the Accelrys product portfolio will provide a single-vendor SILM solution that is already in high demand for product lifecycle management into the critical compliance and quality management arena for science-based process industries.”
 
Research, laboratory and manufacturing informatics applications from Accelrys such as the Electronic Lab Notebook, Laboratory Information Management System, Lab Execution System and Discoverant for Operational Intelligence will serve as data sources and integration points for the compliance and quality business systems managed by QUMAS for corrective action/preventive action (CAPA), annual performance reports and other submissions. QUMAS’ compliance and quality solutions are available as Software as a Service, private cloud or on-premises deployments.
 
“While discovery research remains largely unregulated, it’s clear that the lines across the entire life science value chain are blurring,” said Alan S. Louie, Ph.D., research director, IDC Health Insights.  “As a result, companies are increasingly seeking solutions that allow them to manage new product development more holistically, ensuring that compliance and quality is consistent across the entire product lifecycle. This is becoming a differentiator for organizations seeking to bring innovative new products to market faster and more efficiently, especially as translational efforts become increasingly the norm.”
 
In a commentary on Accelrys’ blog, Carnecchia added that “Approaching product development holistically—across the lab-to-plant continuum—is imperative. We look forward to working with our new colleagues at QUMAS to expand our offerings and to deliver on our [scientific innovation lifecycle management] strategy.”
 
 
SOURCE: Accelrys press release

Kelsey Kaustinen

Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

November 2022 Issue Front Cover

Latest Issue  

• Volume 18 • Issue 11 • November 2022

November 2022

November 2022